From Static Risk to Real-Time Decisions: How AI Enables Autonomic Supply Chain Operations

At LogiPharma 2026 in Vienna, one of the clearest themes across the pharma supply chain conversation was the need to move beyond visibility as a passive capability. For companies managing global, temperature-sensitive and time-critical product flows, the question is no longer simply whether a shipment can be tracked. It is whether the organisation can understand when reality is beginning to diverge from the plan early enough to act.

TransVoyant's AI-driven approach connects real-time signals, enterprise data and ecosystem data to support predictive supply chain decision-making. Image courtesy of TransVoyant.

This was also the central issue explored in Cold Chain Platform's discussion with Allison Fowler, Chief Product Officer at TransVoyant, at the event: how supply chain teams can move from seeing disruption to understanding its consequence in time to respond.

Visibility remains important, but it is no longer sufficient on its own. A shipment may still appear to be moving. A route may still look available. A temperature-controlled product may still be within range. Yet the conditions around that shipment may already be changing in ways that affect dwell time, route reliability, delivery commitment, inventory availability or product integrity.

For pharmaceutical supply chains, the critical gap is often not a lack of data. It is the delay between seeing a disruption and understanding what that disruption means for specific shipments, lanes, products and customer commitments. By the time an alert is triggered, the decision window may already be narrowing.

This is where the conversation shifts from visibility to consequence. The operational question becomes: which shipments are exposed, where risk may surface first, and what actions can still be taken before the impact escalates?

For TransVoyant, this is the context behind Risk in Motion™. Rather than treating risk as a static score or isolated event, the approach focuses on how disruption moves through real-world logistics networks and how it may intersect with specific products, lanes, inventory positions and customer commitments.

From Static Risk to Continuous Decision Intelligence

Pharma supply chains are built on careful planning. Routes are validated, partners are selected, shipment windows are agreed, and product handling requirements are defined in advance. Yet the operating environment around those plans changes constantly.

Traditional planning cycles often work in fixed intervals: monthly, weekly, daily or shipment-by-shipment. In a more stable environment, that may be sufficient. But global pharma logistics now operates in a world where disruption can develop quickly and across multiple layers of the network.

A weather event may affect a route. A geopolitical development may shift risk across a region. A port or airport delay may alter dwell time. A last-mile delivery condition may expose a shipment to unexpected handling or temperature risk. At the same time, customer requirements, product sensitivity and order priority may differ significantly from shipment to shipment.

This is why pharma planning is increasingly moving from a periodic process to a continuous capability. The challenge is not simply to create a plan, but to keep testing that plan against live operating reality.

The strategic question becomes: is the plan still valid, given what is happening now?

TransVoyant describes its platform around the idea of Continuous Decision Intelligence™: connecting data, decisions and intelligent applications so that organisations can move from observing disruption to making faster and more precise execution decisions. Its website also frames the platform around physics-based precision and the ability to understand risk and consequence as they move through global operations.

For pharma supply chains, this distinction matters because risk is rarely static. It moves with the shipment, the lane, the product, the customer commitment and the world around them.

Why Alerts Often Come Too Late

Many supply chain systems were designed to record, track and alert. They provide data on location, status, milestones and exceptions. These capabilities remain important, but they do not always provide enough predictive context.

In complex pharma supply chains, data can sit across multiple systems: ERP, TMS, WMS, visibility platforms, IoT devices, carrier systems, forwarder systems and customer order platforms. Each may provide a useful view, but not necessarily a complete operating picture.

This can create a static view of risk. A lane may be categorised based on historical performance, a shipment may be considered on track because it has not yet missed a milestone, and a temperature-controlled product may appear acceptable because it has not yet crossed a threshold.

By the time most alerts are triggered, the organisation is already reacting to disruption rather than preventing it. The shipment may already be delayed, the product exposed to higher risk, the customer in need of an update, and the recovery window already narrowing.

For pharma, this reactive model is particularly challenging. When products are temperature-sensitive, high-value, time-critical or patient-critical, the cost of late intervention can be significant. The opportunity is to move upstream: from identifying exceptions after they occur to recognising the conditions that may lead to them earlier.

The Three Data Worlds: External, Enterprise and Ecosystem

A central point from the discussion was that autonomic operations depend on connecting different types of data that are often treated separately: external, enterprise and ecosystem data.

• External data includes signals from the world around the shipment, such as weather, geopolitical developments, routing conditions, infrastructure disruption, port or airport congestion, customs conditions and regional risk.
• Enterprise data includes information from within the organisation, including customer orders, shipment plans, inventory priorities, product requirements, service commitments and internal planning assumptions.
• Ecosystem data includes signals from the broader supply chain network, including suppliers, customers, forwarders, carriers, containers, packaging systems, IoT devices, GPS, temperature monitors and handling events.

"The foundation of autonomic operations comes from connecting the data worlds that usually sit apart. Enterprise data tells you what was planned, external signals tell you what is changing around the order, and ecosystem data tells you what is actually happening across suppliers, carriers and logistics partners on the ground. When those signals are combined, companies can understand not only where a shipment is, but whether the plan is still viable and when intervention is needed before disruption impacts product, patient service or supply continuity."

Individually, each data world provides value. Together, they create a more realistic view of supply chain execution.

This connection is important because pharma shipments do not move through a closed system. A shipment plan may be created internally, but the outcome is shaped by external conditions and ecosystem execution. AI-driven operational control becomes more relevant when it can bring these signals together and interpret what they mean for the shipment, the customer order and the product.

Cold Chain as the Clearest Pharma Use Case

For pharma cold chain, the most immediate application is temperature excursion prediction. Temperature-controlled logistics already relies heavily on monitoring. GPS, IoT and temperature data provide critical information about shipment condition and location. However, monitoring alone is not the same as prevention.

A temperature excursion is not always caused by one isolated event. It may be the result of cumulative risk: longer dwell time, route disruption, weather exposure, handling conditions, packaging performance, customs delay or last-mile uncertainty. When these factors are viewed separately, the risk may not be obvious early enough.

AI-driven operational control can help by connecting temperature data with broader context. This may include shipment route, weather, logistics routing, container data, IoT signals, customer order information and on-the-ground conditions. The goal is to identify when a shipment is moving toward higher risk before the product crosses a defined threshold.

For example, TransVoyant points to a recent case in which a global pharma shipper identified a high-risk dwell-time situation 18 hours in advance, enabling the team to reroute the shipment and avoid a temperature excursion. The intervention is estimated to have saved the company in excess of USD 500,000 in potential product loss.

Real-Time Decisions Across Air, Ocean and the Last Mile

The same logic applies across air, ocean and last-mile logistics. A shipment moving by ocean may face congestion, routing changes or schedule disruption. An air shipment may be affected by capacity, weather, customs or handling conditions. A last-mile movement may face local constraints that are not visible through milestone tracking alone.

"In pharma cold chain, the critical question is no longer simply whether you can see a shipment. It is whether you can recognize when the shipment is beginning to move away from its validated path early enough to intervene. If teams can anticipate the conditions that may lead to an excursion, delay, or service failure, they have an opportunity to act before the issue becomes a product-quality, compliance, or patient-impact event."

For pharma companies, this changes the value of visibility. The most valuable alert is not always the one that confirms an excursion has occurred. It may be the signal that allows a team to act before the validated path is compromised.

That could mean intervention with a forwarder, rerouting, escalation, customer communication, replacement planning, change of mode or closer monitoring at a specific handoff point.

In cold chain, prediction is valuable because the consequences of failure can extend beyond logistics performance. Excursions may lead to product waste, investigation, delayed treatment, increased cost and potential patient impact.

AI and Human Intelligence: Earlier Signals, Better Judgement

A key point from the discussion was that AI-driven operational control should not be understood as a replacement for human intelligence. In pharmaceutical supply chains, human judgement remains essential because decisions often involve quality, regulatory, customer, cost and patient-impact considerations that cannot be reduced to a single data point.

The value of AI is to process signals faster, identify emerging operational risk earlier, and enable teams to intervene before disruption impacts product integrity, supply continuity, or patient outcomes. Human intelligence then determines how those options should be interpreted and applied in the context of the product, customer and operating reality.

This balance is particularly important in pharma cold chain operations. A system may identify that a shipment is moving toward higher risk, but the response may depend on product value, remaining stability budget, regulatory obligations, patient need, inventory availability, customer expectations and the feasibility of intervention. These are not purely technical decisions. They require operational judgement.

In this sense, AI supports better human decision-making rather than removing it. Instead of responding only when an exception occurs, teams can begin to manage risk as it develops, supported by earlier, richer and more relevant signals.

From Reactive Logistics to Proactive Pharma Supply Chain Operations

The strategic shift is from reactive logistics to proactive supply chain operations. This does not mean that human decision-making disappears, but that teams are given earlier, richer and more relevant intelligence. Instead of reacting only when a milestone is missed, a temperature threshold is crossed or a customer commitment is at risk, teams can begin to understand where disruption is moving and which decisions are still available.

For pharma supply chains, this shift can support several important outcomes: fewer temperature excursions, reduced product waste, improved service reliability, better customer communication and stronger protection of patient-critical shipments.

It also changes the role of visibility. Visibility is no longer just a way to answer the question, "Where is my shipment?" It becomes part of a broader decision system that asks:

• Is the shipment still aligned with the plan?
• What conditions are changing around it?
• Where may risk surface first?
• What action can still be taken?
• Which shipments matter most from a product, patient or service perspective?

This is where autonomic operations may become increasingly relevant for pharma supply chains. As volatility continues and networks become more complex, the ability to connect data, interpret risk and act earlier will become both an operational advantage and a patient-impact safeguard.

The next stage of visibility may not be seeing more. For pharma companies, it may be seeing earlier, understanding consequence faster, and acting before the shipment, product or patient outcome is at risk.

Allison Fowler, Chief Product Officer at TransVoyant, with Tim Williams, CTO at Cold Chain Platform, at the TransVoyant booth during LogiPharma 2026 in Vienna.

Allison Fowler

Chief Product Officer at TransVoyant

TransVoyant

Tim Williams

CTO at Cold Chain Platform